We are pleased to report that the first shipment of Sucanon diabetes drug has now been sent to Mexico. This portion of our current production will be used for sample packages of Sucanon to be distributed to doctors, pharmacists and buyers for drugstores in Mexico, Mr. Rieveley said.

Sending this shipment is part of fulfilling the requirements for getting Sucanon marketing in Mexico underway, Mr. Rieveley said.

More information on our marketing plan, including radio, TV and print advertising purchases for Mexico, including broadcast in some Spanish-language media in the United States, will be reported shortly, Mr. Rieveley added.

World Health Organization data indicate that over 14% of Mexican adults suffer from Type II Diabetes. With a population of over 110 million, Mexico is one of the largest markets in the world for Type II Diabetes drugs. Type II Diabetes affects over 30 million people in Latin America and more than 18 million in North America.

Biotech Holdings Sucanon is an insulin-sensitizing drug for treatment of symptoms of Type II Diabetes and a related condition, Impaired Glucose Tolerance. The drug, in tablet form, improves patients ability to utilize insulin, the hormone that controls blood sugar levels.

Biotech Holdings has received regulatory approval for sale of the drug in Mexico and Peru as a treatment of Type II Diabetes symptoms. Biotech Holdings has also signed distribution agreements for the drug for Chile, Venezuela, Columbia and Argentina and plans to make regulatory applications for Sucanon in these jurisdictions as well as in Brazil.

If you would you would like to be added to Biotech Holdings email list for future news updates or summary clinical materials, please click here: http://www.biotechltd.com/info.asp